MCE products for research use only. We do not sell to patients.

Dehydrocorydaline chloride

MCE China：Dehydrocorydaline chloride

Brand：MedChemExpress (MCE)

Cat. No.HY-N0674A

CAS：10605-03-5

Synonyms：13-Methylpalmatine chloride

Purity：99.23%

Storage：4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline chloride elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline chloride shows strong anti-malarial effects (IC50 =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.

In Vitro：Treatment of C2C12 myoblasts with 500 nM Dehydrocorydaline increases the expression levels of muscle-specific proteins, including MyoD, myogenin and myosin heavy chain. Treatment with Dehydrocorydaline elevates p38 MAPK activation and the interaction of MyoD with an E protein. Furthermore, defects in differentiation-induced p38 MAPK activation and myoblast differentiation induced by depletion of the promyogenic receptor protein Cdo in C2C12 myoblasts are restored by Dehydrocorydaline treatment[2]. Dehydrocorydaline significantly inhibits MCF-7 cell proliferation in a dose- dependent manner, which can be reversed by a caspase-8 inhibitor, Z-IETD-FMK. Dehydrocorydaline increases DNA fragments without affecting ΔΨm. Western blotting assay shows that dehydrocorydaline dose-dependently increases Bax protein expression and decreases Bcl-2 protein expression. Furthermore, dehydrocorydaline induces activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9. These results show that dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP[1].

In Vivo：Dehydrocorydaline (3.6, 6 or 10 mg/kg, i.p.) shows a dose-dependent antinociceptive effect in the acetic acid-induced writhing test and significantly attenuates the formalin-induced pain responses in mice. In the formalin test, dehydrocorydaline decreases the expression of caspase 6 (CASP6), TNF-α, IL-1β and IL-6 proteins in the spinal cord. These findings confirm that Dehydrocorydaline has antinociceptive effects in mice[4].

Animal Administration：Briefly, the mice are placed individually in glass beakers and are allowed to acclimate for 30 min before the test. The vehicle or Dehydrocorydaline (3.6, 6 or 10 mg/kg) are injected (10 ml/kg, i.p.) 15 min prior to the formalin injection. Morphine (10 mg/kg) or diclofenac sodium (20 mg/kg) are injected 15 and 30 min, respectively, prior to the formalin injection as positive controls. Then, 25 μL of a 5% formalin solution is injected into the plantar surface of the right hind paw of each mouse. Immediately after the formalin injection, the mice are placed individually in the beakers, and a mirror is placed under the beaker to allow clear observation of the paws of the animals. The time that the animals spent on biting/licking the injected paw is measured with a stopwatch every 5 min and considered as indication of nociception.

Cell Assay：Briefly, MCF-7 cells (1×104 cells/well) are seeded in 96-well plates and treated with different concentrations of dehydrocorydaline (0-200 μM) for 24 h. The cell viability is determined. To explore the role of caspase-8 in dehydrocorydaline induced cytotoxicity, a caspase-8 inhibitor Z-IETD-FMK (10 μM) is co-incubated with 200 μM dehydrocorydaline.

IC50 & Target：Plasmodium

Hot selling product：Calcein  | Gliotoxin  | Epcoritamab  | [6]-Gingerol  | Reveromycin A  | (R)-3-Hydroxybutanoic acid  | Inosine  | SB-269970 (hydrochloride)  | Glutathione oxidized  | KL206

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85.  [Content Brief]

[2]. Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36.  [Content Brief]

[3]. Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244.  [Content Brief]

[4]. Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129  [Content Brief]